TEMPUS

Clinic Guide to Tempus Collection Kits

Include two patient identifiers and the date of collection on each sample. Refer to the instructions provided in each kit for important sample collection information.

CARE TEAM GUIDE

Scan here for more information.

TEMPUS KITS

Specimen	Streck tubes with peripheral blood	Oragene container with saliva	EDTA tube with peripheral blood or bone marrow aspirate
Assay	xT CDx Normal Match* xF/xF+ Liquid Biopsy xM **MRD** for CRC	xT CDx Normal Match	xT DNA for heme malignancies xR RNA for heme malignancies



PARTNER KITS

	Personalis	**Ambry**	
Specimen	EDTA tube with peripheral blood + Streck tubes with peripheral blood	EDTA tube with peripheral blood	Oragene container with saliva
Assay	xM **(NeXT Personal® Dx)** for solid tumors	xG/xG+ DNA Hereditary Cancer Testing	xG/xG+ DNA Hereditary Cancer Testing

or

Ambry
EDTA tube with peripheral blood + PAXgene® blood tube
xG/xG+ DNA +RNAinsight® Hereditary Cancer Testing

CONVENIENT COLLECTION OPTIONS

Tempus offers mobile phlebotomy services to make testing accessible for all patients with at-home or onsite blood draws.

If you or your patient has any questions, please call Tempus at 800.739.4137.

Purple Tempus tissue kits are sent directly to pathology labs, where tissue retrieval is managed.

*xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status, using DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens, from previously diagnosed cancer patients with solid malignant neoplasms.The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling. Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product. xT CDx is a single-site assay performed at Tempus AI, Inc., Chicago, IL. For the complete xT CDx label, including companion diagnostic indications and important risk information, please visit tempus.com/xt-cdx-label/